1,2-dimethoxy-3-(methoxymethoxy)benzene | 154045-69-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2-dimethoxy-3-(methoxymethoxy)benzene
• 英文别名: 1,2-Dimethoxy-3-methoxymethoxybenzene
• CAS: 154045-69-9
• 化学式: C₁₀H₁₄O₄
• 分子量: 198.219
• InChiKey: AGZHDDQNVGPZKC-UHFFFAOYSA-N

物化性质

• 沸点：
  263.3±30.0 °C(Predicted)
• 密度：
  1.075±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,2-dimethoxy-3-(methoxymethoxy)benzene 在 盐酸 、 氢化钾 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 37.0h， 生成 butyl-hydroxy-anisole
  参考文献：
  名称：

  Azzena, Ugo; Melloni, Giovanni; Pisano, Luisa, Journal of the Chemical Society. Perkin transactions I, 1995, # 3, p. 261 - 266

  摘要：

  DOI：
• 作为产物：
  描述：

  氯甲基甲基醚 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 以84%的产率得到1,2-dimethoxy-3-(methoxymethoxy)benzene
  参考文献：
  名称：

  [EN] METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS
  [FR] PROCEDES D'ADMINISTRATION D'AGONISTES DU RECEPTEUR DE LA DOPAMINE

  摘要：

  公开号：

  WO2006012640A3

文献信息

• Co-administration of dopamine-receptor binding compounds
  申请人：Fernandes B. Prabhavathi

  公开号：US20070155720A1

  公开（公告）日：2007-07-05

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗患有神经、精神和精神障碍的患者的方法，包括向患者施用部分和/或全多巴胺D1受体激动剂的有效量，并向患者施用多巴胺D2受体拮抗剂的有效量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以以相同或不同的组合或组合物形式向患者施用。
• Method of treatment of dopamine-related dysfunction
  申请人：——

  公开号：US20020132827A1

  公开（公告）日：2002-09-19

  The present invention relates to the treatment of dopamine-related dysfunction using full D 1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “off-period.” The D 1 agonist concentration is reduced during the “off-period” to obtain a plasma concentration of agonist that suboptimally activates D 1 dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises the steps of periodically administering to a patient a full D 1 agonist with a half-life of up to about 6 hours at a dose resulting in a first plasma concentration of agonist capable of activating D 1 dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 hours to obtain a second lower plasma concentration of agonist that results in suboptimal activation of D 1 dopamine receptors for a period of time sufficient to prevent induction of tolerance.

  本发明涉及使用全D1多巴胺受体激动剂在间歇性给药方案中治疗多巴胺相关功能障碍，该方案具有一个短暂但关键的“停药期”。在“停药期”期间，将D1激动剂浓度降低，以获得一段时间的亚最佳激活D1多巴胺受体的激动剂血浆浓度，从而防止耐受性的诱导。具体而言，该方法包括定期向患者施用半衰期长达约6小时的全D1激动剂，剂量产生能够激活D1多巴胺受体以产生治疗效果的第一血浆浓度。至少每24小时减少一次剂量，以获得较低的第二血浆浓度，该浓度导致一段时间的亚最佳激活D1多巴胺受体，足以防止耐受性的诱导。
• Chromeno[4,3,2-DE]isoquinolines as potent dopamine receptor ligands
  申请人：Purdue Research Foundation

  公开号：US06413977B1

  公开（公告）日：2002-07-02

  Novel dopamine receptor ligands of the formula: pharmaceutical formulations of such compounds, and a method using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system, are described. The compounds are expected to be useful in treating Parkinson's disease, improving cognition, improving memory, improving the negative symptoms of schizophrenia, improving attention-deficit hyperactivity disorder and related developmental disorders, treating substance abuse disorders, and in treating various peripheral conditions where changes in dopamine receptor occupation affects physiological function, including organ perfusion, cardiovascular function, and selected endocrine and immune system functions.

  公式：新型多巴胺受体配体的药物制剂，以及使用这些化合物治疗患有中枢或外周神经系统多巴胺相关功能障碍患者的方法。这些化合物有望用于治疗帕金森病、改善认知、改善记忆、改善精神分裂症阴性症状、改善注意力缺陷/多动症及相关发育障碍、治疗物质滥用障碍，以及治疗各种外周条件，其中多巴胺受体占有率的变化影响生理功能，包括器官灌注、心血管功能和选定的内分泌和免疫功能。
• Synthesis of the CD-ring of the anticancer agent streptonigrin: studies of aryl–aryl coupling methodologies
  作者：William T. McElroy、Philip DeShong

  DOI：10.1016/j.tet.2006.04.074

  日期：2006.7

  the success of the coupling process. Analogs of the CD biaryl were prepared by coupling of aryl siloxane derivatives (D-ring component) with highly functionalized 4-bromopyridines (C-ring); however, the CD biaryl of the natural product could not be prepared in high yield by siloxane coupling due to the facile formation of reduced pyridine under the coupling conditions. Alternatively, the fully functionalized

  制备了一系列代表抗癌药链霉菌素C环的功能化4-溴吡啶，并评估了它们与链霉菌素D环硅氧烷进行Pd催化交叉偶联的能力。偶联反应通常耐受受阻CD联芳基的制备。然而，双方的电子效应在耦合过程的成功中起着举足轻重的作用。CD联芳基的类似物是通过将芳基硅氧烷衍生物（D-环组分）与高度官能化的4-溴吡啶（C-环）偶联而制得的。然而，由于在偶联条件下容易形成还原的吡啶，因此不能通过硅氧烷偶联以高产率制备天然产物的CD联芳基。或者，用适当官能化的C-环溴化物和D-环芳基硼酸的Suzuki偶联制备链霉菌素的完全官能化的CD联芳基。所描述的方法是高度收敛的并且容易适用于类似物的合成。
• Design of photoaffinity reagents for labeling the auxin receptor in maize
  作者：Seiji Kosemura、Hideyuki Emori、Shosuke Yamamura、Toyoaki Anai、Kaori Tomita、Koji Hasegawa

  DOI：10.1016/s0040-4039(97)00323-7

  日期：1997.3

  In order to isolate the auxin receptor, we have successfully synthesized two analogues of benzoxazolinones with a trifluoromethyldiazirine group as a photoaffinity probe. These compounds inhibited the auxin-induced growth of etiolated Avena coleoptile segments. Photolyses of these compounds in methanol gave intermolecular OH insertion products in moderate yields, respectively.

  为了分离生长素受体，我们已经成功地合成了具有三氟甲基重氮基团的苯并恶唑啉酮的两个类似物作为光亲和探针。这些化合物抑制了生长素诱导的黄化的Avena胚芽鞘片段的生长。这些化合物在甲醇中的光解分别以中等收率得到了分子间的OH插入产物。